Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 14;44(11):890-899.
doi: 10.3760/cma.j.issn.0253-2727.2023.11.002.

[Impact of SARS-CoV-2 infection on graft composition and early transplant outcomes following allogeneic hematopoietic stem cell transplantation]

[Article in Chinese]
F Lin  1 , H Sun  1 , Y Chen  1 , Y Y Zhang  1 , J Liu  1 , Y He  1 , F M Zheng  1 , Z L Xu  1 , F R Wang  1 , J Kong  1 , Z D Wang  1 , Y Y Wan  1 , X D Mo  1 , Y Wang  1 , Y F Cheng  1 , X H Zhang  1 , X J Huang  1 , L P Xu  1
Affiliations

[Impact of SARS-CoV-2 infection on graft composition and early transplant outcomes following allogeneic hematopoietic stem cell transplantation]

[Article in Chinese]
F Lin et al. Zhonghua Xue Ye Xue Za Zhi. .

Abstract
in English, Chinese

Objective: To assess the feasibility of using donors with novel coronavirus disease 2019 (COVID-19) for allogeneic hematopoietic stem cell transplantation (allo-HSCT) when there are no other available donors and allo-HSCT cannot be delayed or discontinued. Methods: Seventy-one patients with malignant hematological diseases undergoing allo-HSCT between December 8, 2022, and January 10, 2023, were included. Of these, 16 received grafts from donors with mild COVID-19 (D-COVID(+) group) and 55 received grafts from donors without COVID-19 (D-COVID(-) group). The graft compositions were compared between the two groups. Engraftment, acute graft-versus-host disease (aGVHD), overall survival (OS), and relapse were also evaluated. Results: There were no serious side effects or adverse events in the D-COVID(+) group. The mononuclear cell dose and CD34(+) cell dose were comparable between the two groups, and no additional apheresis was required. There were no significant differences in the lymphocyte, monocyte, and T-cell subset doses between the two groups. The median natural killer cell dose in the D-COVID(+) group was significantly higher than that in the D-COVID(-) group (0.69×10(8)/kg vs. 0.53×10(8)/kg, P=0.031). The median follow-up time was 72 (33-104) days. All patients achieved primary engraftment. The 60-day platelet engraftment rates in the D-COVID(+) and D-COVID(-) groups were 100% and (96.4±0.2) %, respectively (P=0.568). There were no significant differences in neutrophil (P=0.309) and platelet (P=0.544) engraftment times. The cumulative incidence of grade 2-4 aGVHD was (37.5±1.6) % vs. (16.4±0.3) % (P=0.062), and of grade 3-4 aGVHD was 25.0% ±1.3% vs. 9.1% ±0.2% (P=0.095) in the D-COVID(+) and D-COVID(-) groups, respectively. The probabilities of 60-day OS were 100% and 98.1% ±1.8% (P=0.522) in the D-COVID(+) and D-COVID(-) groups, respectively. There was no relapse of primary disease during the study period. Conclusion: When allo-HSCT cannot be delayed or discontinued and no other donor is available, a donor with mild COVID-19 should be considered if tolerable. Larger sample sizes and longer follow-up periods are required to validate these results.

目的： 评估供者发生新型冠状病毒感染（COVID-19）时，在没有其他可用供者且异基因造血干细胞移植（allo-HSCT）无法推迟或中止的情况下，使用原计划供者进行allo-HSCT的可行性。 方法： 纳入71例在2022年12月8日至2023年1月10日接受allo-HSCT的恶性血液病患者，其中16例接受轻症新冠病毒感染供者移植物（D-COVID(+)组），55例接受未感染新冠病毒感染供者移植物（D-COVID(－)组）。比较D-COVID(+)组和D-COVID(－)组供者采集物组分，观察两组早期植入、急性移植物抗宿主病（aGVHD）、总生存和复发等结局。 结果： D-COVID(+)组供者未发生严重不良事件。与D-COVID(－)组相比，D-COVID(+)组移植物的单个核细胞（MNC）和CD34(+)细胞计数相当，且无需更多的采集次数。两组淋巴细胞、单核细胞、T细胞亚群分布差异无统计学意义，而D-COVID(+)组移植物中位NK细胞含量高于D-COVID(－)组（0.69×10(8)/kg对0.53×10(8)/kg，P＝0.031）。中位随访时间为72（33~104）d。所有患者均获得粒细胞植入。D-COVID(+)组、D-COVID(－)组移植后60 d血小板植入率分别为100%、（96.4±0.2）%（P＝0.568），并且粒细胞植入、血小板植入时间差异均无统计学意义（P＝0.309，P＝0.544）。D-COVID(+)组、D-COVID(－)组Ⅱ~Ⅳ度aGVHD累积发生率分别为（37.5±1.6）%、（16.4±0.3）%（P＝0.062），Ⅲ/Ⅳ度aGVHD累积发生率分别为（25.0±1.3）%、（9.1±0.2）%（P＝0.095），移植后60 d总生存率分别为100%、（98.1 ± 1.8）%（P＝0.522）。随访期间未发生原发病复发。 结论： 在无替代供者且allo-HSCT无法推迟或中止时，如供者可耐受，可考虑使用轻型新型冠状病毒感染供者按原计划进行移植。.

Keywords: Allogeneic hematopoietic stem cell transplantation; COVID-19; Donor; Malignant hematological disease.

PubMed Disclaimer

Conflict of interest statement

利益冲突 所有作者声明不存在利益冲突

Figures

图1
图1. 供者新冠病毒感染阳性（D-COVID+）组和阴性（D-COVID−）组供者采集物组成比较（*P<0.05，**P<0.001）
图2
图2. 供者新冠病毒感染阳性（D-COVID+）组和阴性（D-COVID−）组异基因造血干细胞移植后细胞免疫重建比较
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Zhang XH, Chen J, Han MZ, et al. The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update[J] J Hematol Oncol. 2021;14(1):145. doi: 10.1186/s13045-021-01159-2. - DOI - PMC - PubMed
    1. Koo J, Auletta JJ, Hartley DM, et al. Secondary Impact of the Coronavirus Disease 19 Pandemic on Patients and the Cellular Therapy Healthcare Ecosystem[J] Transplant Cell Ther. 2022;28(11):737–746. doi: 10.1016/j.jtct.2022.07.020. - DOI - PMC - PubMed
    1. Ueda Oshima M, Sandmaier BM, Petersdorf E, et al. Blood and marrow transplantation during the emerging COVID-19 pandemic: the Seattle approach[J] Bone marrow transplant. 2021;56(2):305–313. doi: 10.1038/s41409-020-01068-x. - DOI - PMC - PubMed
    1. Javed R, Roychowdhury M, Bhave S, et al. Impact of COVID-19 on peripheral stem cell collection and preservation at a hematopoietic cell transplant center in India: Experience 2020[J] Blood Cell Ther. 2021;4(4):84–87. doi: 10.31547/bct-2021-004. - DOI - PMC - PubMed
    1. Luzzi JR, Navarro R, Dinardo CL. COVID-19: Further evidence of no transfusion transmission[J] Transfus Apher Sci. 2021;60(1):102961. doi: 10.1016/j.transci.2020.102961. - DOI - PMC - PubMed

Publication types